Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

doi:10.3390/jcm12041446

. 2023 Feb 11;12(4):1446.

doi: 10.3390/jcm12041446.

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Laeeq Ur Rehman¹, Muhammad Hassan Nisar², Wajeeha Fatima³, Azza Sarfraz⁴, Nishwa Azeem⁵, Zouina Sarfraz⁶, Karla Robles-Velasco⁷, Ivan Cherrez-Ojeda⁷

Affiliations

¹ Department of Research, Continental Medical College, Lahore 54000, Pakistan.
² Department of Research, Aziz Fatima Medical and Dental College, Faisalabad 38000, Pakistan.
³ Department of Research, Quaid e Azam Medical College, Bahawalpur 63100, Pakistan.
⁴ Department of Pediatrics and Child Health, The Aga Khan University, Karachi 74800, Pakistan.
⁵ Schwarzman College, Tsinghua University, Beijing 100190, China.
⁶ Department of Research and Publications, Fatima Jinnah Medical University, Lahore 54000, Pakistan.
⁷ Department of Allergy, Immunology and Pulmonary Medicine, Universidad Espíritu Santo, Samborondón 092301, Ecuador.

PMID: 36835981
PMCID: PMC9966657
DOI: 10.3390/jcm12041446

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Laeeq Ur Rehman et al. J Clin Med. 2023.

. 2023 Feb 11;12(4):1446.

doi: 10.3390/jcm12041446.

Authors

Laeeq Ur Rehman¹, Muhammad Hassan Nisar², Wajeeha Fatima³, Azza Sarfraz⁴, Nishwa Azeem⁵, Zouina Sarfraz⁶, Karla Robles-Velasco⁷, Ivan Cherrez-Ojeda⁷

Affiliations

¹ Department of Research, Continental Medical College, Lahore 54000, Pakistan.
² Department of Research, Aziz Fatima Medical and Dental College, Faisalabad 38000, Pakistan.
³ Department of Research, Quaid e Azam Medical College, Bahawalpur 63100, Pakistan.
⁴ Department of Pediatrics and Child Health, The Aga Khan University, Karachi 74800, Pakistan.
⁵ Schwarzman College, Tsinghua University, Beijing 100190, China.
⁶ Department of Research and Publications, Fatima Jinnah Medical University, Lahore 54000, Pakistan.
⁷ Department of Allergy, Immunology and Pulmonary Medicine, Universidad Espíritu Santo, Samborondón 092301, Ecuador.

PMID: 36835981
PMCID: PMC9966657
DOI: 10.3390/jcm12041446

Abstract

Prostate cancer is the most commonly diagnosed cancer in men worldwide, making up 21% of all cancer cases. With 345,000 deaths per year owing to the disease, there is an urgent need to optimize prostate cancer care. This systematic review collated and synthesized findings of completed Phase III clinical trials administering immunotherapy; a current clinical trial index (2022) of all ongoing Phase I-III clinical trial records was also formulated. A total of four Phase III clinical trials with 3588 participants were included administering DCVAC, ipilimumab, personalized peptide vaccine, and the PROSTVAC vaccine. In this original research article, promising results were seen for ipilimumab intervention, with improved overall survival trends. A total of 68 ongoing trial records pooling in 7923 participants were included, spanning completion until June 2028. Immunotherapy is an emerging option for patients with prostate cancer, with immune checkpoint inhibitors and adjuvant therapies forming a large part of the emerging landscape. With various ongoing trials, the characteristics and premises of the prospective findings will be key in improving outcomes in the future.

Keywords: clinical trials; immunotherapy; men’s health; prostate cancer; therapeutic developments.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
PRISMA flowchart depicting the study selection process.

**Figure 2**
Risk-of-bias assessment of RCTs using the ROB-2 tool. Traffic light plot of study-by-study bias assessment. Weighted summary plot of the overall type of bias encountered in all studies [25,26,27,28].

See this image and copyright information in PMC

Cited by

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.
Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C, Junker-Jensen A, Muthana M, Phillips WA, Pearson HB, Taplin ME, Brown JE, Lewis CE. Al-Janabi H, et al. J Immunother Cancer. 2024 Jul 25;12(7):e009368. doi: 10.1136/jitc-2024-009368. J Immunother Cancer. 2024. PMID: 39060021 Free PMC article.
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer.
Wu F, Wang M, Zhong T, Xiao C, Chen X, Huang Y, Wu M, Yu J, Chen D. Wu F, et al. Exp Hematol Oncol. 2023 Aug 1;12(1):67. doi: 10.1186/s40164-023-00428-9. Exp Hematol Oncol. 2023. PMID: 37528490 Free PMC article.
Comprehensive analysis of macrophage-related genes in prostate cancer by integrated analysis of single-cell and bulk RNA sequencing.
Zhang J, Li Z, Chen Z, Shi W, Xu Y, Huang Z, Lin Z, Dou R, Lin S, Jiang X, Li M, Jiang S. Zhang J, et al. Aging (Albany NY). 2024 Apr 24;16(8):6809-6838. doi: 10.18632/aging.205727. Epub 2024 Apr 24. Aging (Albany NY). 2024. PMID: 38663915 Free PMC article.
Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.
Fieni C, Sorrentino C, Ciummo SL, Fontana A, Lotti LV, Scialis S, Calvo Garcia D, Caulo M, Di Carlo E. Fieni C, et al. Exp Mol Med. 2024 Sep;56(9):2033-2051. doi: 10.1038/s12276-024-01310-2. Epub 2024 Sep 4. Exp Mol Med. 2024. PMID: 39232121 Free PMC article.
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.
Strati A, Economopoulou P, Lianidou E, Psyrri A. Strati A, et al. Biomedicines. 2023 Jun 20;11(6):1768. doi: 10.3390/biomedicines11061768. Biomedicines. 2023. PMID: 37371863 Free PMC article. Review.

See all "Cited by" articles

References

1. Wang I., Song L., Wang B.Y., Kalebasty A.R., Uchio E., Zi X. Prostate Cancer Immunotherapy: A Review of Recent Advancements with Novel Treatment Methods and Efficacy. Am. J. Clin. Exp. Urol. 2022;10:210. - PMC - PubMed
1. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., Meeker A.K., Isaacs W.B., Drake C.G. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. Clin. Cancer Res. 2008;14:3254–3261. doi: 10.1158/1078-0432.CCR-07-5164. - DOI - PMC - PubMed
1. Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic Patterns of Prostate Cancer: An Autopsy Study of 1589 Patients. Hum. Pathol. 2000;31:578–583. doi: 10.1053/hp.2000.6698. - DOI - PubMed
1. Prokhnevska N., Emerson D.A., Kissick H.T., Redmond W.L. Prostate Cancer. Springer; Cham, Switzerland: 2019. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy; pp. 121–147. - PubMed
1. Drake C.G., Doody A.D.H., Mihalyo M.A., Huang C.-T., Kelleher E., Ravi S., Hipkiss E.L., Flies D.B., Kennedy E.P., Long M. Androgen Ablation Mitigates Tolerance to a Prostate/Prostate Cancer-Restricted Antigen. Cancer Cell. 2005;7:239–249. doi: 10.1016/j.ccr.2005.01.027. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources

Full Text Sources

[1] Wang I., Song L., Wang B.Y., Kalebasty A.R., Uchio E., Zi X. Prostate Cancer Immunotherapy: A Review of Recent Advancements with Novel Treatment Methods and Efficacy. Am. J. Clin. Exp. Urol. 2022;10:210. - PMC - PubMed

[2] Wang I., Song L., Wang B.Y., Kalebasty A.R., Uchio E., Zi X. Prostate Cancer Immunotherapy: A Review of Recent Advancements with Novel Treatment Methods and Efficacy. Am. J. Clin. Exp. Urol. 2022;10:210. - PMC - PubMed

[3] Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., Meeker A.K., Isaacs W.B., Drake C.G. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. Clin. Cancer Res. 2008;14:3254–3261. doi: 10.1158/1078-0432.CCR-07-5164. - DOI - PMC - PubMed

[4] Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., Meeker A.K., Isaacs W.B., Drake C.G. Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. Clin. Cancer Res. 2008;14:3254–3261. doi: 10.1158/1078-0432.CCR-07-5164. - DOI - PMC - PubMed

[5] Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic Patterns of Prostate Cancer: An Autopsy Study of 1589 Patients. Hum. Pathol. 2000;31:578–583. doi: 10.1053/hp.2000.6698. - DOI - PubMed

[6] Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic Patterns of Prostate Cancer: An Autopsy Study of 1589 Patients. Hum. Pathol. 2000;31:578–583. doi: 10.1053/hp.2000.6698. - DOI - PubMed

[7] Prokhnevska N., Emerson D.A., Kissick H.T., Redmond W.L. Prostate Cancer. Springer; Cham, Switzerland: 2019. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy; pp. 121–147. - PubMed

[8] Prokhnevska N., Emerson D.A., Kissick H.T., Redmond W.L. Prostate Cancer. Springer; Cham, Switzerland: 2019. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy; pp. 121–147. - PubMed

[9] Drake C.G., Doody A.D.H., Mihalyo M.A., Huang C.-T., Kelleher E., Ravi S., Hipkiss E.L., Flies D.B., Kennedy E.P., Long M. Androgen Ablation Mitigates Tolerance to a Prostate/Prostate Cancer-Restricted Antigen. Cancer Cell. 2005;7:239–249. doi: 10.1016/j.ccr.2005.01.027. - DOI - PMC - PubMed

[10] Drake C.G., Doody A.D.H., Mihalyo M.A., Huang C.-T., Kelleher E., Ravi S., Hipkiss E.L., Flies D.B., Kennedy E.P., Long M. Androgen Ablation Mitigates Tolerance to a Prostate/Prostate Cancer-Restricted Antigen. Cancer Cell. 2005;7:239–249. doi: 10.1016/j.ccr.2005.01.027. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Affiliations

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Related information

Grants and funding

LinkOut - more resources

Full Text Sources